CDTX - Cidara Therapeutics, Inc.
About Cidara Therapeutics, Inc. (https://www.cidara.com)
Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention and treatment of infectious diseases and certain cancers within the U.S. Their primary therapeutic candidate, rezafungin acetate, is an innovative echinocandin antifungal designed to combat and avert severe fungal infections such as candidemia and invasive candidiasis, conditions known for their high fatality rates. Additionally, Cidara utilizes its Cloudbreak platform to engineer conjugated therapies aimed at preventing and treating influenza as well as various other viral illnesses, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and SARS-CoV-2, the pathogen behind COVID-19. Originally incorporated in 2012 as K2 Therapeutics, Inc., the company adopted its current name, Cidara Therapeutics, Inc., in July 2014. Its operations are headquartered in San Diego, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Jeffrey L. Stein | President, Chief Executive Officer & Executive Director | 1955 | $1,098,550 USD |
| Leslie Tari | Chief Scientific Officer | 1967 | $688,050 USD |
| Nicole Davarpanah | Chief Medical Officer | – | $664,600 USD |
| Shane Ward | Chief Operating Officer & Corporate Secretary | 1975 | $620,940 USD |
| Preetam Shah | Principal Accounting Officer | 1973 | $577,850 USD |
| Kevin Forrest | Founder & Chief Strategy Officer | 1977 | $333,313 USD |
| Allison Lewis SPHR | Senior Vice President of People & Culture | – | – |
| Corrina Pavetto | Senior Vice President of Clinical Development | – | – |
| Frank L. Karbe | Chief Financial Officer | 1968 | – |
| Jim Beitel | Chief Business Officer | – | – |